List view / Grid view



Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol

19 November 2014 | By Sanofi / Regeneron Pharmaceuticals

Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…

Sanofi reports positive Phase 3 results for Toujeo®

19 June 2014 | By Sanofi

Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...